Using microscopes to observe tumor vessels
| ISRCTN | ISRCTN10645335 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN10645335 |
| ClinicalTrials.gov number | NCT03517852 |
| Secondary identifying numbers | 17-009823 |
- Submission date
- 06/10/2020
- Registration date
- 25/11/2020
- Last edited
- 13/12/2024
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Plain English summary of protocol
Background and study aims
This study will investigate the tumor-associated vessels of patients with peritoneal carcinomatosis, or cancer that spreads along the inner abdominal lining. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the tumor-associated vessels of peritoneal disease. The IVM observations may determine if an individual patient's tumor vessels would be amenable to receiving systemic treatment, based on the functionality of the vessels.
Who can participate?
Patients who are undergoing surgery for peritoneal carcinomatosis
What does the study involve?
During surgery (CRS-HIPEC), a microscope will be used to directly observe the blood vessels associated with the tumor implants lining the peritoneum (abdominal lining). Intravenous (IV) dyes will be administered through catheters connected to veins in order to help enhance the microscopic observations. These dyes include a substance called fluorescein and indocyanine green, which are two generally safe and frequently used dyes for a variety of surgical procedures. Because there can be allergic reactions to fluorescein (less than 5% of cases), participants will be asked to undergo allergic skin testing to fluorescein before joining the study. This consists of a skin-prick test with a small drop of fluorescein to determine if they will have an allergic reaction. Various measurements of tumor vessels and blood flow through the vessels will be recorded.
What are the possible benefits and risks of participating?
It is not known if participation in this observational study will help or not. Possible help may include identifying tumor characteristics that may someday predict response or guide treatment in the future. Microscopic findings observed during the CRS-HIPEC may have a predictive value of PC response or recurrence. This would potentially result in improved prognostic information for you and other study participants. There is no guarantee of improved outcome for taking part in this study. Future patients may be helped from the results and information gained from this study. It is hoped that information gained in this study will aid in the understanding of cancer and help in the development of new approaches to its treatment.
It is anticipated that there will be minimal-to-no increased risk of adding a microscopic observation to the surgical procedure (CRS-HIPEC). There are, however, inherent risks to CRSHIPEC itself. Studies have shown the complications for which patients undergoing CRS-HIPEC are at risk, including: leaking from any bowel reconnections (only in the case that bowel removal is considered part of the procedure), prolonged recovery time of bowel function (known as an ileus), and/or a decrease in blood counts (such as white blood cells, known as neutropenia) that would be temporary. However, this study is unlikely to increase these risks.
Use of fluorescein may not be recommended in patients with a history of allergic hypersensitivity to fluorescein. Adverse reactions have been reported to occur in 5% or less of patients and are typically mild, including itching or hives. Adverse reactions to indocyanine green have been reported to be even lower with the incidences of mild, moderate and severe reactions to be 0.15%, 0.2% and 0.05%, respectively. Indocyanine green can cause an allergic reaction in patients who are allergic to iodine-based IV contrast dye, typically given during a CT scan. Participants who have an allergic reaction to iodine-based IV contrast dye will not be eligible to participate in this study.
Where is the study run from?
Mayo Clinic Florida (USA)
When is the study starting and how long is it expected to run for?
May 2018 to December 2024
Who is funding the study?
Mayo Clinic Florida Focused Research Teams (USA)
Who is the main contact?
Dr Emmanuel Gabriel
gabriel.emmanuel@mayo.edu
Contact information
Public
Mayo Clinic
4500 San Pablo Road
Jacksonville
32224
United States of America
| Phone | +1 (0)904 953 6691 |
|---|---|
| buchanan.mauricia@mayo.edu |
Scientific
Mayo Clinic
4500 San Pablo Road
Jacksonville
32224
United States of America
| Phone | +1 (0)904 953 2523 |
|---|---|
| Gabriel.Emmanuel@mayo.edu |
Study information
| Study design | Observational single-arm pilot study |
|---|---|
| Primary study design | Observational |
| Secondary study design | Case series |
| Study setting(s) | Hospital |
| Study type | Diagnostic |
| Participant information sheet | https://clinicaltrials.gov/ProvidedDocs/52/NCT03517852/ICF_000.pdf |
| Scientific title | Intravital microscopy in patients with peritoneal carcinomatosis |
| Study acronym | IVM PC |
| Study objectives | This is an observational study. The purpose of this study is to evaluate the microscopic characteristics of the blood vessels associated with tumors that grow along the peritoneum. This type of study is investigational, and it is expected that the use of a special microscope will help visualize tumor-associated blood vessels and blood flow. This may lead to valuable information for physicians in the treatment of patients with this condition. |
| Ethics approval(s) | Approved 04/03/2018, Mayo Clinic Institutional Review Board (Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, USA: +1 (0)866 273 4681; IRBE@mayo.edu), ref: 17-009823 |
| Health condition(s) or problem(s) studied | Peritoneal carcinomatosis |
| Intervention | During surgery (CRS-HIPEC), a microscope will be used to directly observe the blood vessels associated with the tumor implants lining the peritoneum (abdominal lining). Intravenous (IV) dyes will be administered through catheters connected to veins in order to help enhance the microscopic observations. These dyes include a substance called fluorescein and indocyanine green, which are two generally safe and frequently used dyes for a variety of surgical procedures. Because there can be allergic reactions to fluorescein (less than 5% of cases), participants will be asked to undergo allergic skin testing to fluorescein prior to enrollment in the study (as listed above). This consists of a skin-prick test with a small drop of fluorescein to determine if they will have an allergic reaction. Various measurements of tumor vessels and blood flow through the vessels will be recorded. |
| Intervention type | Procedure/Surgery |
| Primary outcome measure | 1. Identify and measure number of vessels associated with peritoneal tumor implants using intravital microscopy at the time of surgery (vessels visualized per high power field) 2. Tumor vessel density (tumor vessels per square cm area observed) as above 3. Number of tumor vessels with fluorescent dye uptake and number of tumor vessels without dye uptake) 4.Tumor blood flow (velocity, mm/sec) of the vessels and tissue penetration of fluorescent dyes as markers of vessel permeability using intravital microscopy at the time of surgery |
| Secondary outcome measures | 1. Diameters, vessel density, detection of intravital dye and flow rates of the microvasculature of peritoneal carcinomatosis compared with normal tissue using intravital microscopy at the time of surgery 2. Pathologic features of the tumor implants (i.e. tumor grade) measured by the investigators at the time of the final pathology report (5-7 days after surgery) 3. Overall survival at 1 and 2 years |
| Overall study start date | 08/05/2018 |
| Completion date | 31/12/2024 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 30 |
| Total final enrolment | 50 |
| Key inclusion criteria | 1. Age ≥18 years of age 2. Have an ECOG Performance Status of ≤2 3. Have measurable disease in the peritoneum by direct visualization (visible lesion typically >0.5 cm in maximal diameter) 4. Carcinomatosis that meets indications for CRS-HIPEC 5. Subject must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure 6. A negative skin-prick test to fluorescein |
| Key exclusion criteria | 1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations 2. Renal dysfunction as defined as a GFR <45 3. Liver dysfunction as defined by Child-Pugh score >5, or LFT's 1.5x above the normal range 4. Any known allergy or prior reaction to fluorescein or ICG or a positive skin prick test to fluorescein 5. Pregnant or nursing female subjects, determined preoperatively with a urine pregnancy test 6. Unwilling or unable to follow protocol requirements 7. Any condition which in the Investigators' opinion deems the patient unsuitable (e.g. abnormal EKG) 8. Any condition that excludes CRS-HIPEC as the standard of care for the patient |
| Date of first enrolment | 15/08/2018 |
| Date of final enrolment | 31/12/2019 |
Locations
Countries of recruitment
- United States of America
Study participating centre
Jacksonville
32224
United States of America
Sponsor information
Hospital/treatment centre
4500 San Pablo Road
Jacksonville
32224
United States of America
| Phone | +1 (0)866 273 4681 |
|---|---|
| IRBE@mayo.edu | |
| Website | https://www.mayo.edu/research/centers-programs/cancer-research/cancer-clinical-trials/cancer-clinical-trials |
Funders
Funder type
Hospital/treatment centre
No information available
Results and Publications
| Intention to publish date | 31/12/2020 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request, Stored in repository |
| Publication and dissemination plan | Planned publication in a high-impact peer-reviewed journal. |
| IPD sharing plan | Current individual participant data (IPD) sharing statement as of 06/01/2022: The datasets generated during and/or analysed during the current study will be stored in a non-publically available repository and will be available on request from the study contact. Previous individual participant data (IPD) sharing statement: The datasets generated during and/or analysed during the current study will be stored in a non-publically available repository. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 02/03/2021 | 06/01/2022 | Yes | No |
Editorial Notes
13/12/2024: The total final enrolment was changed from 30 to 50.
05/12/2023: Contact details updated.
06/01/2022: The following changes have been made:
1. Publication reference added.
2. The overall trial end date has been changed from 31/12/2019 to 31/12/2024 and the plain English summary has been updated accordingly.
3. The individual participant data (IPD) sharing statement has been updated and the IPD sharing summary "Available on request" has been added.
08/10/2020: Trial’s existence confirmed by Mayo Clinic IRB
